glp 1 agonist brands GLP-1 Agonists Examples: Which One Wins? leading brands of glp-1 agonists

Description

The next step will be to carefully design randomized trials that test whether these medications truly lower substance use disorder risk and improve clinical outcomes, while also weighing those possible benefits against known medication side effects

Obes Rev (2022) 23(2):e13372

Additionally, patients with active severe gallbladder disease or bile duct obstruction must avoid GLP-1 medications until their condition resolves completely

Preclinical studies have identified that GLP-1 analogs such as exendin-4 and GLP-1RAs have direct anti-atherosclerotic and anti-inflammatory effects that may contribute to their cardio- and neuroprotective nature.[42] GLP-1RAs can also directly interact with cardiomyocytes, inducing receptor-mediated ischemic conditioning that decreases myocardial infarct size in test animals receiving GLP-1RAs.[43] Similar effects were noted in rodent brains, with liraglutide reducing cerebral infarct volume in rats.[42] Randomized clinical trials (RCTs) also identified that exenatide similarly reduced myocardial infarct size and liraglutide reduced the resulting necrotic area in human patients following a MI.[43] This may account for the reduced need for coronary revascularization in patients on GLP-1RAs.[12] Despite the findings of overall improvements to composite cardiovascular outcomes, GLP-1RAs showed a non-significant trend toward reducing MI risk and did not affect rates of hospitalization for unstable angina in patients with diabetes.[12] These agents tend to have a stronger effect on stroke reduction in such patients, highlighting the complexity and variability of cardiovascular disease and its sequelae

The weight lossassociated improvement in whole-body insulin sensitivity contributes to the improvements in glucose metabolism associated with GLP-1 activity